Shield Therapeutics (LON:STX) Shares Up 11% - Still a Buy?

Key Points

• Shield Therapeutics shares surged by 11%, reaching a high of GBX 9.40 ($0.13) before settling at GBX 9.10 ($0.12).
• The company has a market cap of £97.35 million and a significant debt-to-equity ratio of 3,691.50.
• Shield Therapeutics specializes in delivering Accrufer®/Feraccru®, an innovative treatment for iron deficiency patients.

Shield Therapeutics plc (LON:STX - Get Free Report)'s share price traded up 11% during mid-day trading on Friday . The stock traded as high as GBX 9.40 ($0.13) and last traded at GBX 9.10 ($0.12). 5,965,360 shares traded hands during mid-day trading, an increase of 121% from the average session volume of 2,698,770 shares. The stock had previously closed at GBX 8.20 ($0.11).

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reissued a "buy" rating and issued a GBX 15 price target on shares of Shield Therapeutics in a report on Monday. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Shield Therapeutics currently has an average rating of "Buy" and an average price target of GBX 15.

Shield Therapeutics Trading Down 3.3%

The business's fifty day simple moving average is GBX 5.71 and its 200 day simple moving average is GBX 3.74. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. The stock has a market cap of £81.59 million, a P/E ratio of -391.60 and a beta of 1.42.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.